Potential of Probiotics as an Adjunct for Patients with Major Depressive Disorder

Area of Science:

• Neuroscience
• Microbiology
• Psychiatry

Background:

• Major depressive disorder (MDD) affects 20% of the population, with growing evidence linking it to gut microbiota composition.
• Not all MDD patients respond to current probiotic interventions, necessitating a deeper understanding of the gut-brain axis in depression.
• Existing research suggests a complex interplay between gut microbiota and MDD pathology across different life stages.

Purpose of the Study:

• To comprehensively review the role of gut microbiota, including probiotics, prebiotics, and postbiotics, in the context of MDD.
• To evaluate current MDD management strategies and novel biomaterials, focusing on their therapeutic potential.
• To discuss factors influencing the efficacy of microbiome-targeted therapies for MDD.

Main Methods:

• Literature review of pathological hypotheses, gut microbiota's role in MDD, and current therapeutic interventions.
• Analysis of clinical evidence for probiotics, prebiotics, and postbiotics in MDD patients.
• Evaluation of factors affecting microbiome-based treatments and potential therapeutic targets like the endocannabinoid system.

Main Results:

• The gut microbiota, termed "depression gut microbiota," is implicated in MDD.
• Probiotics, prebiotics, and postbiotics show potential as adjunct therapies for MDD.
• Factors such as diet, physiology, gender, and medication use can modulate treatment efficacy.
• The endocannabinoid system presents a promising target for probiotic-based MDD therapies.

Conclusions:

• While the exact mechanisms require further elucidation, probiotics offer a promising adjunctive approach for managing MDD.
• A holistic understanding of the complex network influencing MDD is crucial for optimizing microbiome-targeted interventions.
• Personalized approaches considering individual factors are essential for successful probiotic-based MDD treatment.